Suppr超能文献

肝硬化:丝氨酸蛋白酶抑制剂对SERPINA4定量的干扰——一项初步研究。

Cirrhosis of liver: Interference of serpins in quantification of SERPINA4 - A preliminary study.

作者信息

Nallagangula Krishna Sumanth, Shashidhar K N, Lakshmaiah V, Muninarayana C

机构信息

Department of Biochemistry, Sri Devaraj Urs Medical College, SDUAHER, Tamaka, Kolar, Karnataka, India.

出版信息

Pract Lab Med. 2017 Oct 7;9:53-57. doi: 10.1016/j.plabm.2017.10.002. eCollection 2017 Dec.

Abstract

BACKGROUND

Cirrhosis of liver is a pathological condition, wherein functions of liver are impaired by chronic liver exploitations. Due to decrease in synthetic capacity, expressions of plasma proteins tend to decrease in blood stream. Serpins (Serine protease inhibitors) are class of plasma proteins expressed from liver with structural similarities and diverse functions. SERPINA4 (Kallistatin) is a multifunctional serpin clade A protein expressed from liver and concentration in serum is the reflection of extent of liver dysfunction.

OBJECTIVE

To identify interference of other serpins by immunological cross reactivity with SERPINA4 in cirrhotic liver and healthy subjects.

MATERIALS AND METHODS

Blood samples were collected from 20 subjects (10 cirrhotic liver, 10 healthy) from R.L. Jalappa Hospital and Research Centre, Kolar, Karnataka, India. Separation of proteins was carried out by SDS-PAGE. Cross reactivity study was analyzed using western blot.

RESULTS

Proteins present in cirrhotic liver and healthy subject's serum were separated by SDS PAGE. There was no band detection on both (cirrhotic liver and healthy) PVDF (polyvinylidene diflouride) membranes. However, a significant band was observed with recombinant kallistatin.

CONCLUSION

Structurally similar serpins with minor amino acid sequence similarities did not show any immunological cross reactivity with SERPINA4 due to non identical epitope in cirrhotic liver and healthy subjects. Present study revealed that there is no interference of serpins for immunological reactions in quantitative estimation of kallistatin which needs further validation.

摘要

背景

肝硬化是一种病理状态,其中肝脏功能因慢性肝脏损伤而受损。由于合成能力下降,血浆蛋白在血流中的表达往往会降低。丝氨酸蛋白酶抑制剂(Serpins)是一类由肝脏表达的血浆蛋白,具有结构相似性和多种功能。SERPINA4(激肽释放酶抑制蛋白)是一种由肝脏表达的多功能丝氨酸蛋白酶抑制剂A类蛋白,血清中的浓度反映了肝功能障碍的程度。

目的

确定肝硬化患者和健康受试者中其他丝氨酸蛋白酶抑制剂与SERPINA4的免疫交叉反应对其的干扰。

材料与方法

从印度卡纳塔克邦科拉尔的R.L.贾拉帕医院和研究中心的20名受试者(10名肝硬化患者,10名健康人)采集血样。通过SDS-PAGE进行蛋白质分离。使用蛋白质印迹法分析交叉反应性研究。

结果

通过SDS-PAGE分离了肝硬化患者和健康受试者血清中的蛋白质。在(肝硬化患者和健康人)聚偏二氟乙烯(PVDF)膜上均未检测到条带。然而,重组激肽释放酶抑制蛋白出现了一条明显的条带。

结论

由于肝硬化患者和健康受试者中存在不同的表位,结构相似但氨基酸序列相似度较小的丝氨酸蛋白酶抑制剂与SERPINA4未显示任何免疫交叉反应。本研究表明,在激肽释放酶抑制蛋白的定量估计中,丝氨酸蛋白酶抑制剂对免疫反应没有干扰,这需要进一步验证。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/676b/5683666/05c9cc06dde2/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验